Clinical Trial Update: Efficacy and Safety of a Two-week Dosing Regimen of Vinorelbine Combined with Liposomal Doxorubicin in the Treatment of HER2-negative Advanced Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a two-week dosing regimen of vinorelbine with liposomal doxorubicin for HER2-negative metastatic breast cancer; the study status is n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Vinorelbine (Vinorelbine)
• liposomal doxorubicin (doxorubicin liposomal)

Snippet

Sponsor: Wang Jiayu | Conditions: Her2-negative Metastatic Breast Cancer, Vinorelbine | Phase 2 | Status: NOT_YET_RECRUITING